CV Lattes
ORCID
Google Scholar Citations
Fundação Pio XII (FP). Hospital do Câncer de Barretos (Institutional affiliation from the last research proposal) Birthplace: Brazil
Graduated in Biotechnology from São Paulo State University, Brazil (2008). Master's degree (2010) and PhD (2014) in Health Sciences, at the São José do Rio Preto Medical School, Brazil. Postdoctoral at Barretos Cancer Hospital (BCH), Molecular Oncology Research Center (2014-2018) and PostDoctoral associate at University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, EUA (2018-2020). Experience in Genetics and Molecular Biology, working mainly in biomarker research for head and neck tumors (DNA methylation, microRNAs, mutations, polymorphisms), cell culture (2D and 3D, co-culture, spheroids and therapeutic response) and tumor immunology, mainly investigating immunological markers of response to immunotherapy (anti-PD-1/PD-L1 and anti-CTLA-4, BCG and imiquimod). Associate researcher and supervisor in the Graduate Program at Institute of Learning and Research, BCH. Coordinator of the Immuno-Oncology group and discipline at the BCH graduate program. Coordinator of the Barretos Cancer Hospital team in the international consortium HEADSpAcE (Translational studies of HEAD and neck cancer in South America and Europe), led by the International Agency for Research on Cancer (IARC) and funded by the European Union. Member of the international consortia MOONRISE (Elucidating the mutational signatures of biological and environmental causes of oral potentially malignant disorders - OPMDs), coordinated by IARC; and Melcaya (Melanomas in Children, Adolescents and Young Adults), both funded by the European Union. Associate Researcher in the FAPESP Thematic Project LOOPS (Identification of non-invasive methods for the early diagnosis of squamous cell carcinoma of the oral cavity and oropharynx) coordinating the Methylome sub-project. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The BD FACSymphony A5 is a cell analyzer that uses the principle of flow cytometry. The equipment has 3 lasers: blue (488nm), red (640nm) and violet (405nm). All three lasers will have a power equal to 100mW and will allow the operator to control them individually via software (on, off and power adjustments). The instrument will be equipped with 21 independent detectors, allowing 21 diffe…
Cancer immunotherapy is based on the premise that tumors can be recognized and can be attacked by an activated immune system. However, tumor cells develop mechanisms to thwart immune recognition and response. The immune checkpoints modulate the homeostasis of co-stimulatory and co-inhibitory signals, which are critical to maintaining immune tolerance besides modulating the physiological i…
Head and neck cancer is a disease with high incidence and mortality, primarily affecting the oral cavity, pharynx, and larynx. Most cases are detected at advanced stages and are associated with low survival rates, frequent recurrences, and poor prognosis, which underscores the importance of early diagnosis to improve clinical outcomes. It is a multifactorial disease, involving both geneti…
Justification: The heterogeneous clinical outcomes observed in patients with advanced melanoma treated with immune checkpoint inhibitors highlight the need to identify predictive biomarkers of response. In this context, the BRAF gene emerges as a potential predictive biomarker due to its activating mutations found in approximately 50% of melanomas, which induce a tumor microenvironment di…
The oral squamous cell carcinoma (OSCC) is a highly aggressive and lethal neoplasm that typically affects the tongue and the floor of mouth in males, smokers and over 50-year-old individuals. The recent rising incidence of OSCC in younger patients (< 40 years old) is altering the lesion epidemiological profile and challenging its treatment. Immunotherapy is the standard or second-line tre…
(Only some records are available in English at this moment)
BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as an alternative treatment for patients with advanced head and neck squamous cell carcinoma (HNSCC) who do not respond to conventional treatments. Together with ICIs, radiotherapy plays an important role in activating the immune system against tumors, proving to be effective in treating these tumors. It is therefore necessary t…
BACKGROUND: Melanoma is the most aggressive cutaneous neoplasm, the main interventions being surgery, chemotherapy or immunotherapy. Despite advances in immune checkpoint inhibitors (ICIs), a significant proportion of patients do not respond to treatment. In a previous study by the Immuno-Oncology group at the Barretos Cancer Hospital (HCB), the CD24 and NFIL3 genes were identified as po…
Background: Several studies aim to improve the diagnosis and treatment of melanoma, emphasizing immunotherapy due to its significant contribution to improving the prognosis in these patients. However, half of patients with metastatic melanoma do not obtain durable survival benefits, motivating the search for markers that identify non-responsive patients. Although histopathological evaluat…
(Only some records are available in English at this moment)
Melanoma, although less common, is the most invasive and lethal cutaneous neoplasm, with an increasing incidence, particularly among individuals with fair skin. Treatment strategies for melanoma include surgery, chemotherapy, radiotherapy, and immunotherapy, with immune checkpoint inhibitors (ICIs) showing significant efficacy in metastatic melanoma. These ICIs target molecules such as CT…
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive liver cancer with limited treatment options and poor prognosis. The tumor microenvironment (TME) significantly influences iCCA progression, drug resistance, and immune evasion. Single-cell and multiomics studies have revealed complex interactions between cancer cells, hepatic stellate cells (HSCs), cancer-associated fibroblasts (CAFs…
Lung cancer causes 1.8 million deaths annually, representing the highest cancer mortality rate, with 85% of patients falling under non-small cell lung cancer (NSCLC). Immunotherapy targeting immune checkpoint inhibitors (ICI) has shown significant advances, employing monoclonal antibodies to modulate co-stimulatory and co-inhibitory signals crucial for immune tolerance maintenance. Despit…
Among the features characterizing the tumor microenvironment (TME), oxygen shortage, namely hypoxia, constitutes a hallmark of most cancer types. It is linked to immunosuppression and associated with the dysregulation of the cellular epigenetic machinery. Interestingly, the differentiation status and functionality of CD8+ T cells are defined by their epigenetic programs. Since the absence…
Programmed Death 1 (PD-1) and T cell Ig and mucin domain-3 protein (Tim-3) are immune checkpoint receptors that are expressed on tumor-infiltrating lymphocytes (TIL) in tumor-bearing mice and humans. As anti-PD-1 single agent response rates are only <20% in head and neck squamous cell carcinoma (HNSCC) patients, it is important to understand how multiple inhibitory checkpoint receptors ma…
| 2 / 2 | Ongoing grants |
| 5 / 5 | Ongoing scholarships in Brazil |
| 15 / 13 | Completed scholarships in Brazil |
| 3 / 3 | Ongoing scholarships abroad |
| 2 / 2 | Completed scholarships abroad |
| 27 / 25 | All research grants and scholarships |
| Associated processes | |